Debt-to-equity in % of Clearside Biomedical, Inc. from Q1 2017 to Q3 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Clearside Biomedical, Inc. quarterly Debt-to-equity history and change rate from Q1 2017 to Q3 2025.
Clearside Biomedical, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -138 %, a 41.4% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Clearside Biomedical, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	-138	+98	+41.4%	30 Sep 2025
Q2 2025	-153	+128	+45.5%	30 Jun 2025
Q1 2025	-172	+193	+52.7%	31 Mar 2025
Q4 2024	-203	+387	+65.5%	31 Dec 2024
Q3 2024	-236	+3,620	+93.9%	30 Sep 2024
Q2 2024	-280	-891	-1.5%	30 Jun 2024
Q1 2024	-366	-586	-2.7%	31 Mar 2024
Q4 2023	-590	-693	-6.8%	31 Dec 2023
Q3 2023	-3,856	-3,902	-85.3%	30 Sep 2023
Q2 2023	610	+589	+27.3%	30 Jun 2023
Q1 2023	219	+193	+7.4%	31 Mar 2023
Q4 2022	101	+64	+1.7%	31 Dec 2022
Q3 2022	45	-18	-28.3%	30 Sep 2022
Q2 2022	21	-53	-71.3%	30 Jun 2022
Q1 2022	26	-74	-73.7%	31 Mar 2022
Q4 2021	37	-92	-71.1%	31 Dec 2021
Q3 2021	63	-71	-52.7%	30 Sep 2021
Q2 2021	75	-72	-48.9%	30 Jun 2021
Q1 2021	99	-43	-30.1%	31 Mar 2021
Q4 2020	129	-11	-7.7%	31 Dec 2020
Q3 2020	134	+15	+12.2%	30 Sep 2020
Q2 2020	146	+60	+68.7%	30 Jun 2020
Q1 2020	142	+84	+1.4%	31 Mar 2020
Q4 2019	140	+102	+2.6%	31 Dec 2019
Q3 2019	120	+82	+2.1%	30 Sep 2019
Q2 2019	87	+51	+1.4%	30 Jun 2019
Q1 2019	58	+24	+67.8%	31 Mar 2019
Q4 2018	38	+2	+6.1%	31 Dec 2018
Q3 2018	38	+13	+48.1%	30 Sep 2018
Q2 2018	36	+14	+65.7%	30 Jun 2018
Q1 2018	35	+14	+65.7%	31 Mar 2018
Q4 2017	36			31 Dec 2017
Q3 2017	26			30 Sep 2017
Q2 2017	22			30 Jun 2017
Q1 2017	21			31 Mar 2017

* An asterisk sign (*) next to the value indicates that the value is likely invalid.